BioAscent is pleased to announce the recent investment in a new NovoCyte 3000 flow cytometer, a cutting-edge piece of equipment that will significantly enhance our capabilities and support our customer projects. The cytometer arrived earlier this year and was installed in February.

The NovoCyte 3000, made by Agilent, uses lasers to interrogate cells, allowing the team at BioAscent to characterise them based on the fluorescence data collected. It is equipped with a NovoSampler Pro, allowing us to run 96-well plates or 24 tubes simultaneously. 

The NovoCyte 3000 offers enhanced sensitivity, detecting up to 17 parameters at once with a customisable laser and optical configuration. This flexibility allows for complex cell analysis, providing high-quality data for immune profiling, cell cycle analysis, and target validation. With rapid data generation and deep insights, we can accelerate the drug discovery process, reducing time and cost while improving the chances of success.

Dr Stuart McElroy, Director of Biosciences says: “Our investment in this high-quality machine from Agilent marks another significant step forward for BioAscent as we continue to expand our capabilities. This advanced technology will allow the biosciences team to perform flow cytometry, a technique we have not been able to do before, adding extra capabilities to existing projects and opening up new opportunities.”

 At BioAscent, we offer high-throughput cell screening, multi-parameter analysis for complex assays, custom assay development, expert data interpretation, and support from our highly experienced scientists.

Contact us today to learn more about our flow cytometry services and how we can help you transform your drug discovery efforts.